Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus
Hoth Therapeutics, Inc. (NASDAQ: HOTH) will host a virtual information session on May 18, 2021, at 11:00 AM ET, focusing on its pipeline product, HT-005 Z-Pods™, a novel endocannabinoid treatment for Cutaneous Lupus Erythematosus (CLE). Dr. Adam Friedman will discuss the treatment's potential, efficacy data from an animal study, and the unmet medical needs it addresses. The session aims to engage shareholders and interested parties. CEO Robb Knie emphasized the company's commitment to innovating therapies for patient needs and driving shareholder value.
- Hosting a virtual information session to engage shareholders and provide updates on HT-005 Z-Pods™.
- Dr. Adam Friedman will present data on the efficacy of HT-005 Z-Pods™ for CLE, highlighting its potential impacts.
- The session underscores Hoth's commitment to addressing unmet medical needs and enhancing patient quality of life.
- None.
NEW YORK, May 13, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today it plans to host a virtual information session on its pipeline product, HT-005 Z-Pods™, a novel endocannibinoid treatment for patients with Cutaneous Lupus Erythematosus (CLE), on Tuesday, May 18th at 11:00am ET for interested shareholders. Adam Friedman, MD, FAAD and Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences, who has worked on the development of this novel therapeutic, will provide an overview on the burden of cutaneous lupus, the gap in care for diagnosed patients, and how HT-005 Z-Pods™ is designed to address both treatment and quality of life concerns for CLE patients. Dr. Friedman will also provide a brief overview of the proof-of-concept efficacy data from an animal study.
"We are excited to share information about HT-005 Z-Pods™ and the potential it has to improve the quality of life and treatment for patients living with Cutaneous Lupus Erythematosus," said Robb Knie, Chief Executive Officer of Hoth Therapeutics, Inc. "Our focus remains on bringing innovative and novel therapeutics through development to address unmet patient needs and drive shareholder value."
This virtual presentation is open to shareholders and any parties interested in learning more about the development of HT-005 Z-Pods™ for the treatment of CLE. Any questions for Hoth Therapeutics and Dr. Friedman can be submitted in advance of the presentation by emailing questions to investorrelations@hoththerapeutics.com.
Meeting Details:
Date: Tuesday May 18, 2021
Time: 11:00am ET
To receive the Zoom meeting details, please click the attached link to register for the event.
https://zoom.us/meeting/register/tJYrcu6trTksE9Esg30dA4rr1a1tCjVQKBlR
After registering, you will receive a confirmation email containing information about joining the meeting.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
Media Relations Contact:
Makovsky
Miriam Brito, Assistant Vice President
Email: hoth@makovsky.com
Phone: (914)-406-0435
View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-provides-shareholder-update-on-novel-endocannabinoid-therapeutic-for-cutaneous-lupus-erythematosus-301290762.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What is the date and time of the Hoth Therapeutics virtual information session?
What will be discussed during the Hoth Therapeutics information session?
Who is presenting at the Hoth Therapeutics virtual session?
How can I register for the Hoth Therapeutics event?
What is the significance of HT-005 Z-Pods™ for patients with Cutaneous Lupus Erythematosus?
